by Plus Therapeutics | Jul 8, 2025 | LM
Plus Therapeutics is pleased to announce that the first patients have been treated in the ReSPECT-LM dose optimization clinical trial, evaluating REYOBIQ™ (rhenium Re 186 obisbemeda) for the treatment of leptomeningeal metastases (LM)—a devastating and often...
by Plus Therapeutics | Jun 30, 2025 | LM
Plus Therapeutics is pleased to announce the initiation of the ReSPECT-LM dose optimization clinical trial for REYOBIQ™ (rhenium Re 186 obisbemeda), a radiotherapeutic designed to target and treat leptomeningeal metastases (LM)—a devastating complication of metastatic...
by Plus Therapeutics | Jun 30, 2025 | Uncategorized
Plus Therapeutics: Advancing the Future of Radiotherapeutics in Cancer Care At Plus Therapeutics, our mission is clear: to address some of the toughest challenges in oncology by improving the efficacy, precision, and convenience of modern radiotherapeutic treatments....
by Plus Therapeutics | Jun 25, 2025 | PBC
We are proud to announce that the U.S. Food and Drug Administration (FDA) has officially cleared Plus Therapeutics’ Investigational New Drug (IND) application for REYOBIQ™, a novel radiotherapeutic under development for the treatment of pediatric patients with...
by Plus Therapeutics | Jun 25, 2025 | PBC
FDA Clears IND for Plus Therapeutics’ REYOBIQ™ in Pediatric Brain Cancer Trial Plus Therapeutics is pleased to announce that the U.S. Food and Drug Administration (FDA) has officially cleared its Investigational New Drug (IND) application for REYOBIQ™, a...
Recent Comments